Search Result

Results for "

fibrinolytic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Autophagy (3) Endogenous Metabolite (1) HIV (3) Liposome (6) Phosphodiesterase (PDE) (3) Thrombin (1)
By Research Areas:	Cancer (5) Cardiovascular Disease (6) Infection (1) Inflammation/Immunology (2) Metabolic Disease (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P2373

Nattokinase, Natto fermentation 1 Publications Verification	Others	Cardiovascular Disease
Nattokinase, Natto fermentation is a potent fibrinolytic enzyme. Nattokinase can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Nattokinase can be used for the research of cardiovascular diseases .

HY-B1399

3-Methylsalicylic acid o-Cresotic acid; Hydroxytoluic acid	Endogenous Metabolite	Cardiovascular Disease
3-Methylsalicylic acid is a salicylic acid derivative that acts on human plasma and has significant fibrinolytic activity by activating the fibrinolytic system.

HY-122052

UK‑396082	Others	Metabolic Disease
UK‑396082 is a potent *thrombin activated fibrinolytic* inhibitor (TAFI)** inhibitor. UK‑396082 increases plasmin activity and induces a parallel decrease in ECM levels. UK‑396082 can be used in research of chronic kidney disease (CKD) .

HY-E70127

Serratiopeptidase Brasan; Dasen	Others	Infection
Serratiopeptidase is an anti-inflammatory agent. Serratiopeptidase has anti-inflammatory, anti-biofilm, mucolytic, fibrinolytic, and wound-healing properties. Serratiopeptidase can be used for combat COVID-19-induced respiratory syndrome research .

HY-155909

m-PEG-NHS ester (MW 3400) mPEG-SC (MW 3400); mPEG-Succinimidyl ester (MW 3400)	Liposome	Others
m-PEG-NHS ester (MW 3400) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.

HY-155909A

m-PEG-NHS ester (MW 1000) mPEG-SC (MW 1000); mPEG-Succinimidyl ester (MW 1000)	Liposome	Others
m-PEG-NHS ester (MW 1000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.

HY-155909B

m-PEG-NHS ester (MW 550) mPEG-SC (MW 550); mPEG-Succinimidyl ester (MW 550)	Liposome	Others
m-PEG-NHS ester (MW 550) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.

HY-155909C

m-PEG-NHS ester (MW 350) mPEG-SC (MW 350); mPEG-Succinimidyl ester (MW 350)	Liposome	Others
m-PEG-NHS ester (MW 350) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.

HY-W591424

m-PEG-NHS ester (MW 2000) mPEG-SC (MW 2000); mPEG-Succinimidyl ester (MW 2000)	Liposome	Others
m-PEG-NHS ester (MW 2000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.

HY-157745

m-PEG-NHS ester (MW 40000) mPEG-SC (MW 40000); mPEG-Succinimidyl ester (MW 40000)	Liposome	Others
m-PEG-NHS ester (MW 40000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects .

HY-P2970

Stem bromelain	Apoptosis	Inflammation/Immunology Cancer
Stem bromelain (EC 3.4.22.32) is a cysteine proteinase, isolated from pineapple (Ananas comosus) stem. Stem bromelain is a major bromelain, which exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Stem bromelain has in vivo antitumoral and antileukemic activity, as well as antimetastatic action .

HY-B0715

Pentoxifylline 5+ Cited Publications BL-191; PTX; Oxpentifylline	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

HY-129056

Melagatran	Thrombin	Cardiovascular Disease
Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia . Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion .

HY-B0715S

Pentoxifylline-d6 BL-191-d₆; PTX-d₆; Oxpentifylline-d₆	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline-d₆ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-B0715S2

Pentoxifylline-d5 BL-191-d₅; PTX-d₅; Oxpentifylline-d₅	Phosphodiesterase (PDE) Autophagy HIV	Cardiovascular Disease Cancer
Pentoxifylline-d₅ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-129611

Bromelain	Apoptosis	Inflammation/Immunology Cancer
Bromelain is an anti-inflammatory agent derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway . Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death .

Cat. No.	Product Name	Type

HY-155909

m-PEG-NHS ester (MW 3400) mPEG-SC (MW 3400); mPEG-Succinimidyl ester (MW 3400)	Drug Delivery
m-PEG-NHS ester (MW 3400) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.

HY-155909A

m-PEG-NHS ester (MW 1000) mPEG-SC (MW 1000); mPEG-Succinimidyl ester (MW 1000)	Drug Delivery
m-PEG-NHS ester (MW 1000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.

HY-155909B

m-PEG-NHS ester (MW 550) mPEG-SC (MW 550); mPEG-Succinimidyl ester (MW 550)	Drug Delivery
m-PEG-NHS ester (MW 550) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.

HY-155909C

m-PEG-NHS ester (MW 350) mPEG-SC (MW 350); mPEG-Succinimidyl ester (MW 350)	Drug Delivery
m-PEG-NHS ester (MW 350) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.

HY-W591424

m-PEG-NHS ester (MW 2000) mPEG-SC (MW 2000); mPEG-Succinimidyl ester (MW 2000)	Drug Delivery
m-PEG-NHS ester (MW 2000) can be used to modify active molecules and improve their antigenicity, immunogenicity, and help prepare injection preparations. The modification of serine protease lumbrokinase (LK) by m-PEG-NHS ester does not affect its strong fibrinolytic and thrombolytic activities, and has good application prospects.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1399

3-Methylsalicylic acid o-Cresotic acid; Hydroxytoluic acid	Cardiovascular Disease Structural Classification Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite Disease Research Fields	Endogenous Metabolite
3-Methylsalicylic acid is a salicylic acid derivative that acts on human plasma and has significant fibrinolytic activity by activating the fibrinolytic system.

HY-P2970

Stem bromelain	Ananas comosus(L.) Merr. Structural Classification Natural Products Classification of Application Fields Bromeliaceae Plants Inflammation/Immunology Disease Research Fields Cancer	Apoptosis
Stem bromelain (EC 3.4.22.32) is a cysteine proteinase, isolated from pineapple (Ananas comosus) stem. Stem bromelain is a major bromelain, which exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Stem bromelain has in vivo antitumoral and antileukemic activity, as well as antimetastatic action .

HY-B0715

Pentoxifylline 5+ Cited Publications BL-191; PTX; Oxpentifylline	Classification of Application Fields Disease Research Fields Cancer	Phosphodiesterase (PDE) Autophagy HIV
Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation .

Cat. No.	Product Name	Chemical Structure

HY-B0715S

Pentoxifylline-d6
Pentoxifylline-d₆ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

Pentoxifylline-d6

Pentoxifylline-d₆ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

HY-B0715S2

Pentoxifylline-d5
Pentoxifylline-d₅ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

Pentoxifylline-d5

Pentoxifylline-d₅ is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks